文献速递神经免疫

50岁以上多发性硬化患者临床复发与疾病结局的关联

Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
PubMed 文献 · Neurology · 2024-06-13

该研究基于德国3个前瞻性队列的二次分析,纳入50岁及以上多发性硬化患者,比较有复发(681例)与无复发对照(232例)的疾病结局。结果显示复发提示潜在活动性疾病,与持续疾病活动和PIRA风险增加相关;基线心血管危险因素和未使用疾病修正治疗为不良结局风险因素。

要点

  • 50岁以上多发性硬化患者中,复发与持续疾病活动及PIRA风险增加相关。
  • 基线存在心血管危险因素和未使用DMT与不良疾病病程相关。
  • 随访期间DMT与稳定而非活动性疾病相关,但与进行性疾病无关。

核心结论

  • 50岁以上多发性硬化患者中提示潜在活动性疾病的复发与持续疾病活动和PIRA风险增加相关。
  • 基线存在心血管危险因素和未使用DMT似乎是不良疾病病程的风险因素。
  • DMT升级转换与稳定而非活动性疾病相关,但与进行性疾病无关。

研究设计与样本

  • 来自德国3个前瞻性队列的二次分析。
  • 复发队列纳入基线访视前≤60天内有复发且随访至少18个月的50岁及以上多发性硬化患者681例(50+:361;55+:220;60+:100)。
  • 对照队列为无复发的多发性硬化患者232例(50+:117;55+:71;60+:44)。
  • 按年龄(50-54岁 vs 55-59岁 vs 60+岁)或疾病结局(稳定 vs 活动 vs 进行性,依据Lublin标准)分层。
  • 采用回归分析评估特定基线风险因素和治疗方案变化与第18个月疾病结局的关联。

主要发现

  • 复发队列 vs 对照队列观察到炎症活动性和非复发依赖的残疾进展增加。
  • 复发队列随访期间273例(59.7%)为稳定,114例(24.9%)为活动,70例(15.3%)为进行性。
  • 心血管危险因素和基线年龄较大被确定为进行性疾病的风险因素,而基线使用DMT有利于稳定疾病。
  • 随访期间DMT与稳定而非活动性疾病相关,但与进行性疾病无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Relapse and MRI activity usually decline with aging but are replaced by progression independent of relapse activity (PIRA) in patients with multiple sclerosis (PwMS). However, several older PwMS continue to experience clinical relapses, and the impact on their disease remains undetermined. We aimed to determine the impact of an index relapse on disease outcomes in patients older than 50 years and to identify risk factors of disadvantageous outcomes. METHODS: We performed a secondary analysis from 3 prospective cohorts in Germany. We evaluated all PwMS 50 years and older with a relapse ≤60 days before a baseline visit and at least 18 months of follow-up compared with a control cohort of PwMS without a relapse. Patients were stratified according to age ("50-54" vs "55-59" vs "60+") or disease outcomes ("stable" vs "active" vs "progressive," according to the Lublin criteria). We analyzed relapses, MRI activity, relapse-associated worsening, and PIRA. Regression analysis was performed to evaluate the association of specific baseline risk factors and treatment regimen changes with disease outcomes at month 18. RESULTS: A total of 681 patients were included in the "relapse cohort" (50+: 361; 55+: 220; 60+: 100). The "control cohort" comprised 232 patients (50+: 117; 55+: 71; 60+: 44). Baseline epidemiologic parameters were balanced among cohorts and subgroups. We observed increased abundance of inflammatory activity and relapse-independent disability progression in the "relapse" vs "control" cohort. In the "relapse" cohort, we identified 273 patients as "stable" (59.7%), 114 patients as "active" (24.9%), and 70 patients as "progressive" (15.3%) during follow-up. Cardiovascular risk factors (CVRFs) and older age at baseline were identified as risk factors of progressive, whereas disease-modifying treatment (DMT) administration at baseline favored stable disease. DMT during follow-up was associated with stable over active, but not over progressive disease. DISCUSSION: A relapse-suggesting underlying active disease-in PwMS older than 50 years was associated with continued disease activity and increased risk of PIRA. Presence of CVRF and absence of DMT at baseline appeared as risk factors of disadvantageous disease courses. An escalation of DMT switch was associated with stable over active but not progressive disease.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pfeuffer S, Wolff S, Aslan D, et al. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years. Neurology. 2024. PMID: 38870471. doi:10.1212/WNL.0000000000209574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。